Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297812 · ClinicalTrials.gov registry record
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
A clinical trial of Genetic Disease and Alpha-1 Antitrypsin Deficiency, sponsored by Columbia University.
- Active
- Registry status
- 286
- Enrollment target
- 9
- Study locations
NCT05297812: Active study of Genetic Disease and Alpha-1 Antitrypsin Deficiency, sponsored by Columbia University.
NCT05297812 is a study of Genetic Disease and Alpha-1 Antitrypsin Deficiency that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 286 participants, below the 2,552-participant average among 30 other Genetic Disease trials with a reported enrollment target (89% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05297812, a study of Genetic Disease and Alpha-1 Antitrypsin Deficiency, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- 286 participants
- Enrollment target
- 9
- Study locations
Study Summary
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
Primary Outcome
Change in lung density over three years determined by using the 15th percentile point of Hounsfield units in inspiratory high resolution CT scans (PERC-15)
Conditions Studied
Study Locations (9)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California - Los Angeles - Los Angeles
Colorado
- National Jewish Health - Denver
Illinois
- University of Chicago - Chicago
Massachusetts
- Boston University - Boston
New York
- Columbia University - New York
North Carolina
- University of North Carolina - Chapel Hill
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2027-01 |
What the registry record for NCT05297812 still lists
NCT05297812 is an observational study that tracks outcomes without assigning an intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, below the 2,552-participant average among 30 other Genetic Disease trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Genetic Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05297812 lists 9 locations in 9 states (Alabama, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05297812 about?
NCT05297812 is a clinical study titled "Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease". Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysem...
What is the current status of trial NCT05297812?
This trial is currently active not recruiting. The enrollment target is 286 participants. The study started on 2022-03-23. Estimated completion is 2027-01.
What conditions does trial NCT05297812 study?
This clinical trial studies the following conditions: Genetic Disease, Alpha-1 Antitrypsin Deficiency.
Who is sponsoring clinical trial NCT05297812?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05297812 being conducted?
This trial has 9 study locations across Alabama, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05297812's enrollment target sits among peer trials
286 15th of 30 higher than 16 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI